Ad
Tuesday, 26 September 2017
FDA pours cold water on PTC Therapeutics' Duchenne application
(Reuters) - PTC Therapeutics Inc has not supplied persuasive evidence that its experimental drug to treat a form of Duchenne muscular dystrophy is effective, a preliminary review by scientists at the U.S. Food and Drug Administration concluded.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment